Colorectal Cancer Liver Metastases: Neoadjuvant Therapy with Bevacizumab

  • Thomas Gruenberger
  • Birgit Gruenberger
Part of the Methods of Cancer Diagnosis, Therapy, and Prognosis book series (HAYAT, volume 4)

Metastatic colorectal cancer (mCRC) is still thought to be a disease resulting in early death in most cases, and patients are depressed by the diagnosis and its dismal prognosis described to them by their physicians. Multidisciplinary teams have, however, considerably changed the survival options, and the combination of effective chemotherapy plus targeted agents and surgery are nowadays lead ing to the potential cure for some mCRC patients. This highly specialized approach to the treatment of mCRC needs to be dis tributed to patients, physicians and health care providers to maximize the potential benefit (Gruenberger et al., 2004).

Advances in the outcome of mCRC patients have been achieved by both medi cal and surgical oncologists, but the most important step was the combination of the knowledge of these specialists in tumor treatment boards where experienced radiologist and radiation therapists were included in a structured algorithm to treat mCRC patients.


Metastatic Colorectal Cancer Portal Vein Embolus Future Remnant Liver Antiangiogenic Therapy mCRC Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adam, R., Pascal, G., Castaing, D., Azoulay, D., Delvart, V., Paule, B., Levi, F., and Bismuth, H. 2004. Tumor progression while on chemo therapy; a contraindication to liver resection for multiple colorectal metastases? Ann. Surg. 240: 1052–1064.PubMedCrossRefGoogle Scholar
  2. Aloia, T., Sebagh, M., Plasse, M., Karam, V., Levi, F., Giacchetti, S., Azoulay, D., Bismuth, H., Castaing, D., and Adam, R. 2006. Liver histol ogy and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J. Clin. Oncol. 24: 4983–4990.PubMedCrossRefGoogle Scholar
  3. Brostjan, C., Gebhardt, K., Greenberger, B., Roka, S., 2008. Neoadjuvant treatment of colorectal cancer with Bevacizumab: the perioperative ang-iogenic balance is sensitive to systemic throm-bospondin-1 levels. Clin. Cancer Research 14: 2065–2074.CrossRefGoogle Scholar
  4. Chong, G., and Cunningham, D. 2005. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J. Clin. Oncol. 23: 9063–9066.PubMedCrossRefGoogle Scholar
  5. Ellis, L., Curley, S., and Grothey, A. 2005. Surgical resection after downsizing of colorectal liver metastasis in the era of Bevacizumab. J. Clin. Oncol. 23: 4853–4855.PubMedCrossRefGoogle Scholar
  6. Ferrara, N., Gerber, H., and LeCouter, J. 2003. The biology of VEGF and its receptors. Nat. Med. 9: 669–676PubMedCrossRefGoogle Scholar
  7. Folkman, J. 1971. Tumor angiogenesis. N. Engl. J. Med. 285: 1182–1186PubMedGoogle Scholar
  8. Fong, Y., Fortner, J., Sun, R., Brennan, M., and Blumgart, L. 1999. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230: 309–321.PubMedCrossRefGoogle Scholar
  9. Gruenberger, T., Schuell, B., Puhalla, H., Schwanzer, E., Bodingbauer, M., Laengle, F., Kornek, G., and Scheithauer, W. 2004. Changes in liver surgery for colorectal cancer liver metas-tases under neoadjuvant treatment strategies. Eur. Surg. 36: 317–321.CrossRefGoogle Scholar
  10. Gruenberger, T., Gruenberger, B., and Scheithauer, W. 2006a. Neoadjuvant Therapy With Bevacizumab. J. Clin. Oncol. 24: 2592–2593.CrossRefGoogle Scholar
  11. Gruenberger, T., Gruenberger, B., Becherer, A., Kettenbach, J, Dieckmann, K., and Schima, W. 2006b. Interdisciplinary management of color-ectal cancer liver metastases. Eur. Surg. 38: 107–111.CrossRefGoogle Scholar
  12. Gruenberger, T., Tamandl, D., Puhalla, H., Scheithauer, W., Zielinski, C., and Gruenberger, B. 2007. Bevacizumab plus XELOX as neo-adjuvant therapy for patients with poten tially curable metastatic colorectal cancer. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25, 18 S (June 20 Supplement): 4064.Google Scholar
  13. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. 2004. Bevacizumab plus irinotecan, fluorou-racil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350: 2335–2342.PubMedCrossRefGoogle Scholar
  14. Jain, R. 2001. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med 7: 987–989.PubMedCrossRefGoogle Scholar
  15. Kesmodel, S., Ellis, L., Lin, E., Chang, G., Abdalla, E., Kopetz, S., Vauthey, J., Rodrigues-Bigas, M., Curley, S., and Feig, B. 2007. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. ASCO GI meet ing abstract. Abstract 234.Google Scholar
  16. Rubbia-Brandt, L., Audard, V., Sartoretti, P., Roth, A. D., Brezault, C., Le Charpentier, M., Dousset, B., Morel, P., Soubrane, O., Chaussade, S., Mentha, G., and Terris, B. 2004. Severe hepatic sinusoi dal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorec-tal cancer. Ann. Oncol. 15: 460–466.CrossRefGoogle Scholar
  17. Saltz, L., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitzer, M., Yang, T., and Cassidy, J. 2007a. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treat ment of metastatic colorectal cancer (MCRC). ASCO GI meeting abstract. Abstract 238.Google Scholar
  18. Saltz, L., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitzer, M., Yang, T., and Cassidy, J. 2007b. Updated efficacy results from XELOX-1/NO16966, a randomised phase III trial in first-line metastatic colorectal cancer: analysis of bevacizumab in combination with XELOX or FOLFOX-4. Ann. Oncol. 18(Suppl.7): vii21 (abstract O-0032).Google Scholar
  19. Wray, C., Rilo, H., and Ahmad, S. 2004. Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin. Invest. Drugs 13: 631–41.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2009

Authors and Affiliations

  • Thomas Gruenberger
    • 1
  • Birgit Gruenberger
    • 1
  1. 1.Department of General SurgeryMedical University of ViennaViennaAustria

Personalised recommendations